Single Ascending Dose Study With BPL-003 in Healthy Subjects
NCT ID: NCT05347849
Last Updated: 2024-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
62 participants
INTERVENTIONAL
2022-02-14
2024-01-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
NCT05032833
Acute Dose-dependent Effects of DMT in Healthy Subjects
NCT05384678
BXCL501 After Stress to Increase Recovery Success
NCT06943404
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)
NCT05695495
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
NCT02333071
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BPL-003 arm
BPL-003
A single dose of BPL-003 will be administered intranasally
Placebo arm
Placebo
A single dose of placebo will be administered intranasally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BPL-003
A single dose of BPL-003 will be administered intranasally
Placebo
A single dose of placebo will be administered intranasally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
25 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beckley Psytech Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
VP & Head of Clinical Development, PhD
Role: STUDY_DIRECTOR
Beckley Psytech Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hammersmith Medicines Research
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rucker JJ, Roberts C, Seynaeve M, Young AH, Suttle B, Yamamoto T, Ermakova AO, Dunbar F, Wiegand F. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. J Psychopharmacol. 2024 Aug;38(8):712-723. doi: 10.1177/02698811241246857. Epub 2024 Apr 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BPL-003-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.